Oxygen Biotherapeutics, Inc. Release: University of Glasgow Study Demonstrates the Ability of Oxycyte® to Supply Oxygen to Critical Penumbral Tissue in Acute Ischemic Stroke

Published: Aug 21, 2012

MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (“OBI”) (NASDAQ: OXBT) announced today that recent research conducted by its partner, Aurum Biosciences (“Aurum”), Glasgow, Scotland, has shown that Oxycyte®, OBI’s proprietary perfluorocarbon-based intravenous emulsion, improves imaging of the penumbra following acute ischemic stroke in a rat model. The penumbra is the region of the brain where blood supply is inadequate to support normal brain function but sufficient to maintain tissue viability for a limited period of time following stroke. It represents potentially salvageable tissue which, if the oxygen supply can be restored, could lead to improved functional outcomes for stroke patients.

Back to news